Targeting	O
wide	O
-	O
range	O
oncogenic	O
transformation	O
via	O
PU24FCl	O
,	O
a	O
specific	O
inhibitor	O
of	O
tumor	B-Cancer
Hsp90	O
.	O

Agents	O
that	O
inhibit	O
Hsp90	O
function	O
hold	O
significant	O
promise	O
in	O
cancer	B-Cancer
therapy	O
.	O

Here	O
we	O
present	O
PU24FCl	O
,	O
a	O
representative	O
of	O
the	O
first	O
class	O
of	O
designed	O
Hsp90	O
inhibitors	O
.	O

By	O
specifically	O
and	O
potently	O
inhibiting	O
tumor	B-Cancer
Hsp90	O
,	O
PU24FCl	O
exhibits	O
wide	O
-	O
ranging	O
anti	O
-	O
cancer	B-Cancer
activities	O
that	O
occur	O
at	O
similar	O
doses	O
in	O
all	O
tested	O
tumor	B-Cancer
types	O
.	O

Normal	O
cells	B-Cell
are	O
10	O
-	O
to	O
50	O
-	O
fold	O
more	O
resistant	O
to	O
these	O
effects	O
.	O

Its	O
Hsp90	O
inhibition	O
results	O
in	O
multiple	O
anti	O
-	O
tumor	B-Cancer
-	O
specific	O
effects	O
,	O
such	O
as	O
degradation	O
of	O
Hsp90	O
-	O
client	O
proteins	O
involved	O
in	O
cell	B-Cell
growth	O
,	O
survival	O
,	O
and	O
specific	O
transformation	O
,	O
inhibition	O
of	O
cancer	B-Cell
cell	I-Cell
growth	O
,	O
delay	O
of	O
cell	B-Cell
cycle	O
progression	O
,	O
induction	O
of	O
morphological	O
and	O
functional	O
changes	O
,	O
and	O
apoptosis	O
.	O

In	O
concordance	O
with	O
its	O
higher	O
affinity	O
for	O
tumor	B-Cancer
Hsp90	O
,	O
in	O
vivo	O
PU24FCl	O
accumulates	O
in	O
tumors	B-Cancer
while	O
being	O
rapidly	O
cleared	O
from	O
normal	O
tissue	B-Tissue
.	O

Concentrations	O
achieved	O
in	O
vivo	O
in	O
tumors	B-Cancer
lead	O
to	O
single	O
-	O
agent	O
anti	O
-	O
tumor	B-Cancer
activity	O
at	O
non	O
-	O
toxic	O
doses	O
.	O

